Learn about the impact Gout has on patients and healthcare in our interview with noted rheumatologist, Dr. N. Lawrence Edwards 

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.) is a clinical stage biotechnology company founded in 2012. Atom is developing best-in-class orally delivered small molecule drugs for treatment of inflammatory and metabolic diseases, such as chronic gout and non-alcoholic steatohepatitis (NASH) for which there are no effective treatments.

Atom’s lead therapy, ABP-671, for chronic gout, is more potent and significantly less toxic than existing drugs, and is poised to enter global Phase 3 trials in 2022. Another compound, ABP-6016, has demonstrated safety and efficacy in preclinical trials for NASH, which is projected to become the most common cause of liver disease.

Latest News from Atom Bioscience

02 November, 2026
Atom Therapeutics to Present Phase 2b/3 Data Showing Superior Efficacy of Lingdolinurad (ABP-671), Compared to Febuxostat, for Patients with Chronic Gout and Hyperuricemia at ACR Convergence 2026
PRESS RELEASE Atom...
26 October, 2026
Atom Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Lingdolinurad (ABP-671) for Chronic Kidney Disease with Hyperuricemia
PRESS RELEASE Atom...
23 June, 2026
Atom Therapeutics Announces First Patient Dosed in China Phase 3 Clinical Trial of Lingdolinurad (ABP-671) for Chronic Gout
PRESS RELEASE Atom...
15 June, 2026
Atom Therapeutics to Update Clinical Trials of Its Lead Drugs, a URAT1 Inhibitor for Chronic Gout and New Anti-Inflammatory Drug for Acute Gout Flares, at the BIO International Convention 2026 in San Diego
PRESS RELEASE Atom...
More Atom News